An 18-mer ASO called AP12009 (trabedersen) that targets TGF-β2 expression in glioma, pancreatic carcinoma, and malignant melanoma has been tested in a phase III clinical trial for astrocytoma showed better survival outcomes in astrocytoma patients [19,154,155,156,175]. The gene discussed is TGFB2; the disease is astrocytoma (excluding glioblastoma).